GelSana

Healing Wounds *Faster*

Leadership

Melissa Krebs, Ph.D.
Founder & CEO
Associate Professor,
Colorado School of Mines
22 years research experience

Investor
Mike Freeman, CEO,
Innosphere Ventures

Markets

- Wound care
- Diabetic wound care
- Chronic wound care

Financial Information

Company Stage: Seed
Capital: Innosphere Fund
(pre-seed $150k and seed lead $550k)
Capital Seeking: $250,000 seed

Contact Information

GelSana Therapeutics
Melissa Krebs, Ph.D.
Founder & CEO
mdkrebs@gelsanatherapeutics.com



What We Do

GelSana is developing novel wound healing hydrogels that heal tissues faster than other products on the market, reducing the risk of infection. We are initially targeting diabetic ulcers which are difficult to resolve, and which can result in limb amputation (over 80,000 per year occur in the U.S.). The materials from which our hydrogels are made have been shown to be anti-inflammatory and prevent the foreign body response when in contact with the body. In animal studies, we have demonstrated the ability for our hydrogels to heal diabetic wounds faster, matching the rate of healthy wound healing. These materials also offer controlled delivery of therapeutics to promote even faster healing for chronic wounds that may need drugs provided over time to fully resolve.

Business Model

GelSana's strategy is to develop a superior line of wound dressings, introducing a gel-only product under the 510(k) medical device classification. We are also developing GelSana dressings that include therapeutics released in a sustained manner over time. We are building a unique patent portfolio to protect the value of these impactful products for chronic wounds. We intend to partner and license the products for commercialization with a leader in the wound healing space.

Current Traction

We have received pre-seed and seed funding from Innosphere Ventures. We have one granted patent and 3 patent applications pending. We have animal data showing efficacy of our hydrogels alone, which can heal diabetic wounds 1.5x faster than untreated, and our hydrogels laden with an anti-inflammatory drug (non-FDA approved) that heals diabetic wounds 2x faster than untreated wounds.

Problem

Diabetes is a vast and growing health problem all over the world. Diabetics are at high risk of developing diabetic ulcers, chronic wounds that won't heal readily on their own. In the U.S., a diabetic develops a difficult-to-heal ulcer every 1.2 seconds. Half of these ulcers will get infected and ultimately lead to surgical amputations, which happen every 20 seconds. Their cost including patient care and time out of work is estimated at $78B/yr in the U.S.

Market

The global wound care market is around $22B, with about $8.5B of that currently spent on wound dressings for ulcer care specifically (moists, biologics, and anti-infectives). GelSana's hydrogel-only product would fit into the moist category; with the advantage of being inherently anti-inflammatory it will be a strong competitor to existing products. Drug-laden versions would be considered anti-infective or biologics.

Competitors

Company	Product	Primary Product Composition
Smith+Nephew	Intrasite Gel	Carboxymethyl Cellulose
Smith+Nephew	Regranex	Platelet-derived growth factor in carboxymethyl cellulose
Cardinal Health	Aquaflo	Polyurethane
Coloplast	Purilon Gel	Carboxymethyl Cellulose and Alginate